HilleVax Inc HLVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HLVX is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.88–1.95
- 52-Week Range
- $1.55–20.22
- Bid/Ask
- $1.85 / $1.92
- Market Cap
- $93.97 Mil
- Volume/Avg
- 622,261 / 974,673
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 90
- Website
- https://www.hillevax.com
Comparables
Valuation
Metric
|
HLVX
|
ICVX
|
PCVX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.39 | 3.30 | 4.61 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
HLVX
ICVX
PCVX
Financial Strength
Metric
|
HLVX
|
ICVX
|
PCVX
|
---|---|---|---|
Quick Ratio | 10.92 | 17.59 | 17.25 |
Current Ratio | 10.92 | 18.06 | 17.42 |
Interest Coverage | −56.32 | — | — |
Quick Ratio
HLVX
ICVX
PCVX
Profitability
Metric
|
HLVX
|
ICVX
|
PCVX
|
---|---|---|---|
Return on Assets (Normalized) | −34.73% | −29.30% | −20.32% |
Return on Equity (Normalized) | −44.29% | −31.87% | −21.78% |
Return on Invested Capital (Normalized) | −39.50% | −34.69% | −26.68% |
Return on Assets
HLVX
ICVX
PCVX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Bwqwlqywlz | Nqwh | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Gkvpqnqk | Rytkfx | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Lnwgkqbt | Qqrzc | $118.7 Bil | |||
Moderna Inc
MRNA
| Jkdbsrsc | Jnnfw | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Hkjkmvjl | Rsylyp | $29.7 Bil | |||
argenx SE ADR
ARGX
| Jynrpvbwp | Cnns | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Mshckzj | Kkhg | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Zdwqhqg | Pbxmpvx | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Znxdhtyn | Gnsm | $15.0 Bil | |||
Incyte Corp
INCY
| Tqjxmdl | Pkghwh | $13.5 Bil |